Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
Date:10/30/2007

sident and chief

executive officer of Gilead Sciences, Inc., has been elected to its

board of directors. Gen-Probe's board now has eight members,

including seven who are not Gen-Probe employees.

-- Update on PROCLEIX ULTRIO Post-Marketing Study. To date,

participating blood banks have screened approximately 260,000 blood

donations in the post-marketing study for the PROCLEIX ULTRIO assay,

which is designed to demonstrate hepatitis B virus (HBV) "yield."

Yield is defined as HBV-infected blood donations that were intercepted

by the PROCLEIX ULTRIO assay, but that were initially negative based

on traditional serology tests. Gen-Probe believes that the first of

two required yield cases has been identified in the study, although

this must be confirmed through a regulatory submission to the FDA.

The FDA has approved the PROCLEIX ULTRIO assay to screen donated blood

for HIV-1 and hepatitis C virus (HCV), but not to screen for HBV, as

the initial clinical studies were not designed to, and did not,

demonstrate HBV yield. Gen-Probe and Novartis are conducting the

post-marketing study to demonstrate HBV yield and gain the associated

donor screening claim.

Webcast Conference Call

A live webcast of Gen-Probe's third quarter 2007 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (800) 947-6450 for domestic callers and (203) 369-3539 for international callers.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic aci
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced ... officer, will present at the Oppenheimer 20th Annual Healthcare Conference ... 9:40 a.m. Eastern Time , To access the live and ... company,s website at http://www.pdl.com and click "Investors." Please ...
... 27 Organogenesis, Inc. Chief Medical Officer Dr. Damien ... prestigious TEDMED medical innovation conference beginning today in San ... Come From?" will outline developments in the emerging and ... of patient lives. , The field of regenerative medicine ...
... PRINCETON, N.J., Oct. 27 Soligenix, Inc., (Soligenix or ... DOR BioPharma, Inc., a late-stage biotechnology company, announced today ... a company overview highlighting recent developments at the BIO ... Thursday, October 29, 2009 at 1:00 PM PDT at ...
Cached Biology Technology:Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference 2Soligenix to Present at 8th Annual BIO Investor Forum 2Soligenix to Present at 8th Annual BIO Investor Forum 3Soligenix to Present at 8th Annual BIO Investor Forum 4
(Date:4/17/2014)... Mo. April 17 In the most densely forested ... forests reflect two centuries of human needs, values and ... and clearing forests for agriculture and development, have set ... a U.S. Forest Service study reports. , The report ... conditions and management needs in the Northern United States ...
(Date:4/17/2014)... 17, 2014The development of stem cell therapies to cure ... characterize stem cell populations based on cell surface markers. ... new marker that is highly expressed in a type ... which they describe in an article in BioResearch ... Liebert, Inc., publishers. The article is available free on ...
(Date:4/17/2014)... ALBUQUERQUE, N.M. A credit-card-sized anthrax detection cartridge developed ... small business makes testing safer, easier, faster and cheaper. ... causes anthrax, is commonly found in soils all over ... illness in both humans and animals. The bacteria can ... to B. anthracis may occur through skin ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... Two years ago, a group of friends were enjoying ... Germany when their conversation turned to the health benefits which ... making wine, by-products are left over which are often just ... by-products contain the goodness of wine in an even more ...
... presented in the name of Engineering Conferences International ... be awarded to Professor Sakayu Shimizu of Kyoto ... both fundamental and applied sciences. He has contributed ... functions, reactions and enzymes as biotechnological tools for ...
... by Hebrew University of Jerusalem researchers of an additional role ... step in world-wide efforts to develop genetic regulation aimed at ... The molecule, known as Lysyl-tRNA synthetase (or LysRS ... the cell, where it has long been recognized for its ...
Cached Biology News:The wonders of wine 2The wonders of wine 3Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award 2
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: